MIT Scientist to Present at BIO 2015
MIT scientist Robert Langer will speak at BIO 2015 on a panel about venture capitalism in biotechnology.
Robert Langer, MIT scientist and professor, will be speaking on a panel at the BIO International Convention 2015. The panel, Thirty Years of Venture Capitalism in Biotechnology, will take place on June 15, 2015 at 12:30 pm EST and will feature discussions on the history of venture capitalism in biotechnology, how it has shaped the industry, and how it has changed over time. Langer, the 2014 winner of the Biotechnology Heritage Award, which is presented by the Chemical Heritage Foundation every year at BIO Convention, will be joined on the panel by two other winners of this award: Moshe Alafi (2015 winner), a venture capitalist in biotechnology, and Joshua Boger (2011 winner), an entrepreneur and co-founder of Vertex Pharmaceuticals.
For more information on BIO International Convention 2015, please visit BIO 2015. The convention will be held June 15 to June 18, 2015 in Philadelphia, PA at the Philadelphia Convention Center.
Source: BioTech Now
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
